RightFit
RecruitingPhase not listed

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
60 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether frailty checks, which measure weakness and physical fitness, can predict how older adults will do after cancer treatment. It is for people age 60 or older with certain blood cancers or related conditions who may receive chemotherapy, CAR T-cell therapy, or a stem cell transplant from a donor.

The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Both groups: Age 60 or older.
  • Both groups: Able to agree to join the study.
  • Group A: A new or suspected diagnosis of acute leukemia (a fast-growing blood cancer) or MDS (a condition where bone marrow makes abnormal blood cells).
  • Group B: Have a blood cancer.
  • Group B: Plan to have a blood or bone marrow stem cell transplant from a donor, or CAR T-cell therapy (treatment that changes your immune cells to fight cancer).

Who can't join

    Simplified for readability. The official criteria below are what the study team uses.

    Official eligibility criteria

    Eligibility Criteria Arm A: * Age 60 years or older. * New diagnosis of Acute Leukemia or MDS, or suspected diagnosis. * Able to consent to the study. Eligibility Criteria Arm B: * Age 60 years or older with a hematologic malignancy. * Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy. * Able to consent to the study.

    Study sites (1)

    PA